ScholarIQanswers from OpenAlex & ORCID
Kenneth B. Gordon
ResearcherPublications, citations & collaboration network
Kenneth B. Gordon is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Kenneth B. Gordon have?
ScholarIQindexed works
Kenneth B. Gordon has 304 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kenneth B. Gordon have?
ScholarIQcitation count
Kenneth B. Gordon has 26,113 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Kenneth B. Gordon?
ScholarIQh-index
Kenneth B. Gordon has an h-index of 74 in OpenAlex.
What is the i10-index of Kenneth B. Gordon?
ScholarIQi10-index
Kenneth B. Gordon has an i10-index of 167 in OpenAlex.
What is the ORCID of Kenneth B. Gordon?
ScholarIQorcid
The ORCID for Kenneth B. Gordon is on the source record.
What is the OpenAlex record for Kenneth B. Gordon?
ScholarIQopenalex
The OpenAlex for Kenneth B. Gordon is on the source record.
What are the most-cited papers on Kenneth B. Gordon?
ScholarIQmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, Darío Kivelevitch, Elizabeth Farley Prater, Benjamin K. Stoff, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Marie R. Davis, Boni E. Elewski, Joel M. Gelfand, Kenneth B. Gordon, Alice B. Gottlieb, Arthur Kavanaugh, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Craig L. Leonardi, Jason Lichten, Henry W. Lim, Nehal N. Mehta, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Reena Rupani, Michael Siegel, Emily Wong, Jashin J. Wu, Vidhya Hariharan, Craig A. Elmets
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, Richard G. Langley, Thomas A. Luger, Mamitaro Ohtsuki, Kristian Reich, David A. Amato, Susan Ball, Daniel Braun, Gregory S. Cameron, J. Erickson, Robert J. Konrad, Talia M. Muram, Brian J. Nickoloff, Olawale Osuntokun, Roberta J. Secrest, Fangyi Zhao, Lotus Mallbris, Craig L. Leonardi
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula